Collegium Pharmaceutical Inc Total Liabilities
Collegium Pharmaceutical Inc total liabilities. Based on the latest financial reports, Collegium Pharmaceutical Inc (COLL) has total liabilities worth $1.33 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Collegium Pharmaceutical Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Collegium Pharmaceutical Inc (2013–2024)
Total liabilities of Collegium Pharmaceutical Inc from 2013 to 2024. This chart illustrates how Collegium Pharmaceutical Inc's total liabilities have evolved over time, based on quarterly financial data.
Collegium Pharmaceutical Inc Competitors by Total Liabilities
The table below lists competitors of Collegium Pharmaceutical Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Medplus Health Services Limited
NSE:MEDPLUS
|
India | Rs19.58 Billion |
|
Hangzhou Jingye Intelligent Technology Co. Ltd. A
SHG:688290
|
China | CN¥493.75 Million |
|
Thunder Tiger Corp
TW:8033
|
Taiwan | NT$1.00 Billion |
|
Trident Digital Tech Holdings Ltd American Depository Shares
NASDAQ:TDTH
|
USA | $12.10 Million |
|
Hubei Huaqiang High-Tech Co. Ltd. A
SHG:688151
|
China | CN¥536.38 Million |
|
Logistea AB Series B
ST:LOGI-B
|
Sweden | Skr11.19 Billion |
|
ZhuZhou QianJin Pharmaceutical Co Ltd
SHG:600479
|
China | CN¥1.70 Billion |
|
Zhejiang Grandwall Electric Science&Technology Co Ltd Class A
SHG:603897
|
China | CN¥4.23 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Collegium Pharmaceutical Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Collegium Pharmaceutical Inc (COLL) total assets.
Liquidity & Leverage Metrics
Collegium Pharmaceutical Inc Total Liabilities Ratios Explained
Collegium Pharmaceutical Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Collegium Pharmaceutical Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Collegium Pharmaceutical Inc (2013–2024)
The table below shows the annual total liabilities of Collegium Pharmaceutical Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.43 Billion | +51.36% |
| 2023-12-31 | $947.88 Million | -3.21% |
| 2022-12-31 | $979.29 Million | +100.20% |
| 2021-12-31 | $489.15 Million | +6.85% |
| 2020-12-31 | $457.81 Million | +109.17% |
| 2019-12-31 | $218.87 Million | +9.62% |
| 2018-12-31 | $199.66 Million | +534.08% |
| 2017-12-31 | $31.49 Million | +16.15% |
| 2016-12-31 | $27.11 Million | +114.37% |
| 2015-12-31 | $12.65 Million | -27.03% |
| 2014-12-31 | $17.33 Million | +402.06% |
| 2013-12-31 | $3.45 Million | -- |
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more